Drug Type Mesenchymal stem cell therapy |
Synonyms HUC-MSCs (Vcanbiopharma), Human Umbilical Cord-derived Mesenchymal Stem Cells (Vcanbiopharma), VUM 02 + [2] |
Target- |
Mechanism Stem cell replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Graft Versus Host Disease | Phase 2 | CN | 13 May 2024 | |
type 2 diabetes mellitus with peripheral neuropathy | Phase 2 | CN | 19 May 2022 | |
type 2 diabetes mellitus with peripheral neuropathy | Phase 2 | CN | 19 May 2022 | |
Idiopathic Pulmonary Fibrosis | Phase 1 | CN | 01 Feb 2024 | |
Acute-On-Chronic Liver Failure | IND Approval | CN | 07 Jun 2023 | |
Respiratory Distress Syndrome, Adult | IND Approval | CN | 07 Jun 2023 | |
Decompensated cirrhosis of liver | IND Approval | CN | 10 Feb 2023 |